Amvuttra 25 mg solution for injection in pre-filled syringe, Onpattro 2 mg/mL concentrate for solution for infusion.
ALN-TTRSC02-002
Phase 3 small_molecule active
Quick answer
Amvuttra 25 mg solution for injection in pre-filled syringe, Onpattro 2 mg/mL concentrate for solution for infusion. for Hereditary Transthyretin Amyloidosis is a Phase 3 program (small_molecule) at Alnylam Netherlands B.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Alnylam Netherlands B.V.
- Indication
- Hereditary Transthyretin Amyloidosis
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active